gemcitabine has been researched along with aee 788 in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Abbruzzese, JL; Chiao, PJ; Fidler, IJ; Hamilton, SR; He, J; Kim, SJ; Nam, DH; Sasaki, T; Sclabas, GM; Thaker, P; Yazici, S; Yokoi, K | 1 |
| Abbruzzese, JL; Baker, CH; Bucana, CD; Fan, D; Fidler, IJ; Kitadai, Y; Kuwai, T; Sasaki, T; Yokoi, K | 1 |
| Finn, RS; Zhu, AX | 1 |
1 review(s) available for gemcitabine and aee 788
| Article | Year |
|---|---|
Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Carcinoma, Hepatocellular; Clinical Trials as Topic; Cytotoxins; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Neoplasm Proteins; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaliplatin; Purines; Quinazolines; RNA, Small Interfering; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
3 other study(ies) available for gemcitabine and aee 788
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Induction of apoptosis in tumor-associated endothelial cells and therapy of orthotopic human pancreatic carcinoma in nude mice.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Endothelial Cells; ErbB Receptors; Exons; Gemcitabine; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Male; Mice; Mice, Nude; Microcirculation; Microscopy, Fluorescence; Neoplasm Transplantation; Pancreatic Neoplasms; Phosphorylation; Platelet Endothelial Cell Adhesion Molecule-1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Purines; Receptors, Vascular Endothelial Growth Factor | 2005 |
Simultaneous inhibition of EGFR, VEGFR, and platelet-derived growth factor receptor signaling combined with gemcitabine produces therapy of human pancreatic carcinoma and prolongs survival in an orthotopic nude mouse model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Growth Processes; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Endothelial Cells; ErbB Receptors; Gemcitabine; Humans; Imatinib Mesylate; Immunohistochemistry; In Situ Nick-End Labeling; Male; Mice; Mice, Nude; Pancreatic Neoplasms; Phosphorylation; Piperazines; Platelet Endothelial Cell Adhesion Molecule-1; Purines; Pyrimidines; Receptor Protein-Tyrosine Kinases; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Xenograft Model Antitumor Assays | 2005 |